NCT06035016招募中不适用
A Prospective, Multicenter and Registry-based Cohort Study of Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- 3-year IDFS
研究概览
简要总结
This is a prospective, multicenter, registry-based cohort study to explore the efficacy and safety of Pyrotinib combined with Capecitabine for adjuvant treatment of HER2 positive early breast cancer compared with treatment of physician's choice. Pyrotinib is a small molecule tyrosine kinase inhibitor which can irreversibly inhibit HER1, HER2, and HER4.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female patients ≥ 18 years and ≤ 75 years old;
- •Primary invasive breast cancer confirmed by histology;
- •HER2 positive breast cancer (IHC 3+, or IHC 2+ and FISH positive); lymph node positive, except for T0; lymph node negative and tumor >1cm, or tumor > 0.5 cm and ≤ 1cm, and accompanied by any of the following high-risk factors: pathological grade 3, ER/PR negative, or < 35 years old;
- •Having received mastectomy or breast conserving surgery, and received sentinel lymph node biopsy or axillary lymph node dissection, and within 90 days from the breast surgery;
- •With known ER/PR status of breast cancer;
- •ECOG score 0-1;
- •The patient's major organ functions meet all of the following requirements for blood tests:
- •Neutrophil count (ANC) ≥ 1,500/mm3 (1.5×109/L);
- •Platelet count (PLT) ≥ 75,000/mm3 (75×109/L);
- •Hemoglobin (Hb) ≥ 8 g/dL (80 g/L);
- •Serum creatinine (SCr) ≤ 1.5 times the upper limit of normal (ULN) or creatinine clearance ≥ 60 mL/min;
- •Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN);
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≤ 2.5 times the upper limit of normal (ULN), patients with liver metastases should be ≤ 5×ULN.
- •The participant voluntarily joins the study, signs the informed consent form, has good compliance, and cooperates with follow-ups.
- •Exclusion criteria:
- •Breast cancer recurs before enrollment, or local recurrence/ metastasis confirmed by radiology;
- •The subject has participated in other clinical trials within 4 weeks or 5 half-lives (whichever is longer) before enrollment;
- •The patient has previously received treatment including tyrosine kinase inhibitors targeting HER2 (e.g., lapatinib, neratinib, and pyrotinib);
- •The patient has been diagnosed with other malignancies within 5 years of enrollment, except for cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin which has been cured;
- •The patient is receiving anti-tumor therapies from other clinical trials;
- •Inability to swallow, chronic diarrhea, or intestinal obstruction, with multiple factors affecting drug administration and absorption;
- •The patient has undergone major surgical procedures unrelated to breast cancer within 4 weeks of enrollment, or has not fully recovered from such surgical procedures;
- •With known allergies to any components of the agents to be administered in this study; history of acquired or congenital immunodeficiency diseases, including HIV; history of HCV, active hepatitis B, or history of organ transplantation;
- •Pregnant and lactating patients, patients of fertility unwilling to take effective contraceptive measures throughout the trial;
- •With any heart disease including: (1) arrhythmia requiring medication or clinical attention; (2) myocardial infarction; (3) heart failure; (4) any other heart diseases that are considered unsuitable to the trial;
- •With any comorbidities that are considered to potentially endanger the patient's safety or interfere with the study, including but not restricted to resistant hypertension, severe diabetes, active infection, etc.;
- •With a history of neurological or mental disorders, including but not restricted to epilepsy or dementia;
- •The patient is using CYP3A4 inhibitors or inducers, or any other drugs that potentially prolong the QT interval;
- •Any other circumstances in which the researcher believes that the patient is not suitable to participate in this study.
排除标准
- 未提供
研究组 & 干预措施
cohort A
Pyrotinib 400mg, qd, po, day 1-21, q3w, Capecitabine 1000mg/m2, bid po d1-14, q3w
干预措施: pyrotinib combined with Capecitabine (Drug)
cohort B
treatment of physician's choice
干预措施: treatment of physician's choice (Drug)
结局指标
主要结局
3-year IDFS
时间窗: 3 Year
The 3-year IDFS (invasive disease-free survival) is defined as the time from the date of enrollment to the first occurrence of recurrent diseases. Recurrent diseases include ipsilateral or contralateral recurrent breast cancer, local or regional recurrence, remote recurrence and death caused by any reason. The observation period is from enrollment to 3 years after enrollment.
次要结局
- AEs and SAEs(3 Year)
- QoL(3 Year)
研究者
Qiang SUN
Professor
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Revive AIS Patients ImmeDiatelyIschemic StrokeOcclusion, CerebrovascularNCT03007082Changhai Hospital100
已完成
不适用
Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo TransferInfertility, FemaleNCT05130125LG Chem1,166
Unknown
不适用
Study Evaluating the Safety and Efficacy of Tri-wire Balloon for Treatment of Dysfunctional AV FistulaArteriovenous FistulaNCT04393688BrosMed Medical Co., Ltd168
已完成
不适用
TC-A Registration StudyPrimary OsteoarthritisRheumatoid ArthritisAvascular NecrosisPost-traumatic ArthritisNCT02139345Smith & Nephew Medical (Shanghai) Ltd162
招募中
2 期
The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.Non-Small Cell Lung CancerNCT04777084Hunan Province Tumor Hospital120